Session » 3S084: Systemic Sclerosis & Related Disorder – Clinical I: Therapeutics & Outcomes (863–868)
- 2:30PM-4:00PM
- 
				Abstract Number: 864
 Change in Scleroderma Skin Histology Correlates with the Combined Response Index in Systemic Sclerosis (CRISS) in Patients with Early, Diffuse Cutaneous Systemic Sclerosis
- 2:30PM-4:00PM
- 
				Abstract Number: 866
 Evaluation of the Highly Selective Endothelin a Receptor Antagonist Zibotentan in Systemic Sclerosis Associated Chronic Kidney Disease
- 2:30PM-4:00PM
- 
				Abstract Number: 867
 Safety and Efficacy of B-cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension in a Multi-center NIH Clinical Trial
- 2:30PM-4:00PM
- 
				Abstract Number: 865
 Safety and Efficacy of Lenabasum at 21 Months in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
